achieves durable clinical benefit in early trial

KRAS inhibitor sotorasib appears safe, achieves durable clinical benefit in early trial

Sep 21, 2020

Phase I study encouraging for patients with advanced cancers and KRAS G12C mutations ABSTRACT: 1257O HOUSTON ― In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and […]

The Community Hero page celebrates the individuals and organizations making a lasting difference in Katy and the surrounding areas. Each month, we spotlight local heroes whose dedication, compassion, and hard work inspire others—whether they’re first responders, educators, volunteers, business owners, or everyday residents stepping up to help their neighbors.

Through personal stories, interviews, and photos, we honor their contributions and shine a light on the positive impact they have in our community. By sharing their journeys, we hope to encourage others to get involved, foster connections, and remind everyone that small acts of kindness can spark big change.

If you know someone whose efforts deserve recognition, let us know—they could be our next Community Hero.